12/10/2018 18:00:00

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MGTI, ACHC and ADNT

Related content
07 Dec - 
Analysis: Positioning to Benefit within Snap, Kansas Ci..
06 Dec - 
New Research Coverage Highlights G1 THERAPEUTICS, Schlu..
03 Dec - 
CLASS ACTION DEADLINE for TGTX, ACHC and ADNT: Levi & K..

NEW YORK, Oct. 12, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.        

MGT Capital Investments Inc. (OTCMKTS: MGTI)

Class Period: October 9, 2015 to September 7, 2018

Lead Plaintiff Deadline: November 27, 2018

During the class period, MGT Capital Investments Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants were engaged in an illegal pump-and-dump scheme to artificially inflate MGT Capital’s stock price; (2) the "Scheme Defendants"--Defendants Ladd, Honig, Stetson, Brauser, O’Rourke, and Groussman--had a history of engaging in illegal conduct in connection with the purchase and sale of securities; (3) the Scheme Defendants were a “group”, pursuant to Section 13 of the Exchange Act; (4) the Scheme Defendants exercised control over the Company; (5) the Company’s acquisition of D-Vasive Inc. was part of Defendants’ illegal pump-and-dump scheme to artificially inflate MGT Capital’s stock price; (6) Defendants’ illicit scheme caused MGT Capital to make false and misleading statements, which would result in governmental and regulatory scrutiny; (7) the scheme would result in the delisting of MGT Capital’s stock from NYSE MKT; and (8) as a result, Defendants’ statements about MGT Capital’s business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Get additional information about the MGTI lawsuit: https://www.kleinstocklaw.com/pslra-1/mgt-capital-investments-inc-loss-submission-form?wire=3

Acadia Healthcare Company, Inc. (NASDAQGS: ACHC)

Class Period: February 23, 2017 to October 24, 2017

Lead Plaintiff Deadline: December 3, 2018

The complaint alleges Acadia Healthcare Company, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the quality of Acadia’s U.K. operations did not give the Company a “competitive strength” that would drive future growth and profitability; and (2) defendants had no reasonable basis to believe--and did not in fact believe--their positive statements about the Company’s business and financial prospects during the Class Period, including their guidance issued and reaffirmed throughout the Class Period.

Get additional information about the ACHC lawsuit: https://www.kleinstocklaw.com/pslra-1/acadia-healthcare-company-inc-loss-submission-form?wire=3

Adient plc (NYSE: ADNT)

Class Period: October 31, 2016 to June 11, 2018

Lead Plaintiff Deadline: December 3, 2018

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements. In particular, the complaint alleges that defendants repeatedly stressed to investors that the Company was “solidly on track” to deliver 200-basis-point margin expansion by 2020, which was largely dependent on operational and financial improvements in Adient’s core SS&M business, while unbeknownst to investors, Adient’s core SS&M business faced significant operational problems such that the repeatedly touted 200-basis-point margin expansion was not “on track” at any point during the Class Period. Consequently, Adient stock traded at artificially inflated prices during the Class Period, reaching a high of $85.93 per share.

Get additional information about the ADNT lawsuit: https://www.kleinstocklaw.com/pslra-1/adient-plc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Joseph Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

Klein NEW logo black transparent.png

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Voyager Therapeutics Announces First Patient Dosed in RESTORE-1, a Phase 2 Trial of VY-AADC Gene Therapy for the Treatment of Parkinson’s Disease
2
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
3
Uptick Newswire’s Stock Day Podcast Hosts Medifocus, Inc.’s CEO to Discuss Their Minimally Invasive Breakthrough Treatments for Prostate and Breast Cancers
4
WISeKey Secures Printer Systems, from Cartridge to Cloud, with WISePrint@Cloud
5
Flame Seal Products FS-PG Wildfire Protection System Proves Totally Effective in Raging California Wildfire

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
11 December 2018 03:10:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB7 - 2018-12-11 04:10:41 - 2018-12-11 03:10:41 - 1000 - Website: OKAY